
Samsung Biologics Acquires GSK’s Manufacturing Facility in Maryland, US
The acquisition marks Samsung Biologics’ geographical diversification, establishing its first US manufacturing presence and expanding regional client support.

The acquisition marks Samsung Biologics’ geographical diversification, establishing its first US manufacturing presence and expanding regional client support.

GSK announced a definitive agreement to acquire RAPT Therapeutics for $2.2 billion, gaining rights to ozureprubart, a next-generation treatment that could protect food allergy patients.















